Company News
TiumBio Shows 75% First‑Line Response
TiumBio presented Phase 2a data for Tosposertib plus Keytruda in recurrent/metastatic head‑neck squamous cell carcinoma at ASCO.
In 12 first‑line patients, the combo achieved a 75% overall response ra
